Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 28

The DOI matches its Crossref record.

Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8–9

Minici, Roberto, Ammendola, Michele, Manti, Francesco, Siciliano, Maria Anna, Minici, Marco, Komaei, Iman, Currò, Giuseppe, Laganà, Domenico · 2021 · Frontiers in Pharmacology

Abstract

According to the EASL Guidelines for the management of hepatocellular carcinoma, transcatheter arterial chemoembolization is the first-line treatment recommended for intermediate-stage HCC. Furthermore, it is widely accepted that patients beyond the Milan criteria can be considered for a liver transplant after successful downstaging to within the Milan criteria. Response to downstaging treatments significantly influences not just drop-outs, but also the rate of post-transplantation tumor recurrences. TACE with degradable starch microspheres represents an alternative to conventional TACE with lipiodol and TACE with drug-eluting beads, and it leads to transient arterial occlusion allowing lower activation of hypoxia-inducible factors and less release of vascular endothelial growth factor, a promoter of neoangiogenesis, tumor proliferation, and metastatic growth. In patients with intermediate-stage HCC and a Child-Pugh score of 8 or 9, life expectancy may be dominated by cirrhotic liver dysfunction, rather than by the tumor progression itself; hence, locoregional treatments might also be detrimental, precipitating liver dysfunction to an extent that survival is shortened rather than prolonged. Data on tolerability, toxicity, and effectiveness of DSM-TACE are limited but encouraging. Between January 2015 and October 2020, 50 consecutive patients with intermediate-stage hepatocellular carcinoma and a Child-Pugh score of 8/9, who had undergone DSM-TACE as the first-line treatment, were eligible for the study. A total of 142 DSM-TACEs were performed, with a mean number of 2.84 procedures per patient. The mean time-to-downstaging was 19.2 months, with six patients successfully downstaged. OS was about 100% at six months, 81.8% at 12 months, and 50% at 24 months. Twenty-two patients experienced adverse events after chemoembolization. The median OS and safety of DSM-TACE in this study are comparable with other published investigations in this field. Furthermore, 12% of patients were successfully downstaged. Hence, the results of the current investigation demonstrate that DSM-TACE is effective and safe in intermediate-stage HCC, achieving an interesting downstaging rate. Such data were observed in the population subset with a Child-Pugh score of 8 or 9, in which life expectancy may be determined by cirrhotic liver dysfunction, so the achievement of a balance between the safety and efficacy profile of the TACE treatment is crucial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2021.634087

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 37

  1. Affonso, 2019, Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging, World J. Gastroenterol., 25, 5687, 10.3748/wjg.v25.i37.5687 · DOI
  2. Aronsen, 1979, Controlled blocking of hepatic artery flow with enzymatically degradable microspheres combined with oncolytic drugsflow with enzymatically degradable microspheres combined with oncolytic drugs, Eur. Surg. Res., 11, 99, 10.1159/000128056 · DOI
  3. Basile, 2012, Quality-improvement guidelines for hepatic transarterial chemoembolization, Cardiovasc. Intervent. Radiol., 35, 765, 10.1007/s00270-012-0423-z · DOI
  4. Bolondi, 2012, Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisionsfication to facilitate treatment decisions, Semin. Liver Dis., 32, 348, 10.1055/s-0032-1329906 · DOI · Paper page
  5. Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: A Cancer J. Clin., 68, 394, 10.3322/caac.21492 · DOI · Paper page
  6. Brown, 2016, Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone, Jco, 34, 2046, 10.1200/jco.2015.64.0821 · DOI · Paper page
  7. Bryce, 2017, Downstaging for hepatocellular cancer: harm or benefit?, Transl. Gastroenterol. Hepatol., 2, 106, 10.21037/tgh.2017.11.18 · DOI
  8. Burrel, 2012, Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design, J. Hepatol., 56, 1330, 10.1016/j.jhep.2012.01.008 · DOI · Paper page
  9. Cucchetti, 2011, Improved diagnostic imaging and interventional therapies prolong survival after resection for hepatocellular carcinoma in cirrhosis: the university of bologna experience over 10 years, Ann. Surg. Oncol., 18, 1630, 10.1245/s10434-010-1463-8 · DOI
  10. Ebert, 2013, Intravital microscopic research of microembolization with degradable starch microspheres, J. Drug Delivery, 2013, 1, 10.1155/2013/242060 · doi:10.1155/2013/242060
  11. Filippiadis, 2017, Cirse quality assurance document and standards for classification of complications: the cirse classification systemfication of complications: the cirse classification system, Cardiovasc. Intervent. Radiol., 40, 1141, 10.1007/s00270-017-1703-4 · DOI · Paper page
  12. Forner, 2010, Current strategy for staging and treatment: the BCLC update and future prospects, Semin. Liver Dis., 30, 061, 10.1055/s-0030-1247133 · DOI · Paper page
  13. Galle, 2018, EASL clinical practice guidelines: management of hepatocellular carcinoma, J. Hepatol., 69, 182, 10.1016/j.jhep.2018.03.019 · DOI · Paper page
  14. Golfieri, 2014, Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma, Br. J. Cancer, 111, 255, 10.1038/bjc.2014.199 · DOI · Paper page
  15. Gross, 2020, Transarterial chemoembolisation (TACE) with degradable starch microspheres (DSM) and anthracycline in patients with locally extensive hepatocellular carcinoma (HCC): safety and efficacy, Cardiovasc. Intervent Radiol., 43, 402, 10.1007/s00270-019-02364-w · doi:10.1007/s00270-019-02364-w
  16. Gruber-Rouh, 2018, Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: comparative study, BMC Cancer, 18, 188, 10.1186/s12885-018-4099-x · doi:10.1186/s12885-018-4099-x
  17. Kang, 2020, Conventional versus small doxorubicin-eluting bead transcatheter arterial chemoembolization for treating Barcelona clinic liver cancer stage 0/A hepatocellular carcinoma, Cardiovasc. Intervent Radiol., 43, 55, 10.1007/s00270-019-02349-9 · doi:10.1007/s00270-019-02349-9
  18. Kirstein, 2017, Experience from a real-life cohort: outcome of 606 patients with hepatocellular carcinoma following transarterial chemoembolization, Scand. J. Gastroenterol., 52, 116, 10.1080/00365521.2016.1233579 · doi:10.1080/00365521.2016.1233579
  19. Lammer, 2010, Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study, Cardiovasc. Intervent. Radiol., 33, 41, 10.1007/s00270-009-9711-7 · DOI · Paper page
  20. Lencioni, 2016, Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety dataficacy and safety data, Hepatology, 64, 106, 10.1002/hep.28453 · DOI · Paper page
  21. Lencioni, 2010, Modified RECIST (mRECIST) assessment for hepatocellular carcinoma, Semin. Liver Dis., 30, 052, 10.1055/s-0030-1247132 · DOI · Paper page
  22. Li, 2004, Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level, World J. Gastroenterol., 10, 2878, 10.3748/wjg.v10.i19.2878 · DOI · Paper page
  23. Llovet, 1999, Prognosis of hepatocellular carcinoma: the BCLC staging classification, Semin. Liver Dis., 19, 329, 10.1055/s-2007-1007122 · DOI · Paper page
  24. Llovet, 2003, Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival, Hepatology, 37, 429, 10.1053/jhep.2003.50047 · DOI · Paper page
  25. Llovet, 2002, Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial, Lancet, 359, 1734, 10.1016/s0140-6736(02)08649-x · DOI · Paper page
  26. Lo, 2002, Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma, Hepatology, 35, 1164, 10.1053/jhep.2002.33156 · DOI · Paper page
  27. Mazzaferro, 2009, Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis, Lancet Oncol., 10, 35, 10.1016/s1470-2045(08)70284-5 · DOI · Paper page
  28. Mazzaferro, 2011, Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience, Liver Transpl., 17, S44, 10.1002/lt.22365 · DOI · Paper page
  29. Niessen, 2014, Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma, J. Vasc. Interv. Radiol., 25, 240, 10.1016/j.jvir.2013.10.007 · doi:10.1016/j.jvir.2013.10.007
  30. Oken, 1982, Toxicity and response criteria of the eastern cooperative oncology group, Am. J. Clin. Oncol., 5, 649, 10.1097/00000421-198212000-00014 · DOI · Paper page
  31. Orlacchio, 2015, Downstaging disease in patients with hepatocellular carcinoma outside up-to-seven criteria: strategies using degradable starch microspheres transcatheter arterial chemo-embolization, World J. Hepatol., 7, 1694, 10.4254/wjh.v7.i12.1694 · doi:10.4254/wjh.v7.i12.1694
  32. Parikh, 2015, Downstaging hepatocellular carcinoma: a systematic review and pooled analysis, Liver Transpl., 21, 1142, 10.1002/lt.24169 · DOI · Paper page
  33. Sieghart, 2013, The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma, Hepatology, 57, 2261, 10.1002/hep.26256 · DOI · Paper page
  34. Varela, 2007, Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics, J. Hepatol., 46, 474, 10.1016/j.jhep.2006.10.020 · DOI · Paper page
  35. Vogel, 2018, Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol., 29, iv238, 10.1093/annonc/mdy308 · DOI · Paper page
  36. Yao, 2015, Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria, Hepatology, 61, 1968, 10.1002/hep.27752 · DOI · Paper page
  37. Zhang, 2018, Association of sustained response duration with survival after conventional transarterial chemoembolization in patients with hepatocellular carcinoma, JAMA Netw. Open, 1, e183213, 10.1001/jamanetworkopen.2018.3213 · DOI

Cited by

See all 28

Metadata

Authors
Minici, R., Ammendola, M., Manti, F., Siciliano, M. A., Minici, M., Komaei, I., Currò, G., & Laganà, D.
Venue
Frontiers in Pharmacology
Published
2021-04-08
Volume
12
ISSN
1663-9812
Cited by
28
References
0

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8–9. https://app.cochat.ai/papers/10.3389/fphar.2021.634087
The paper
Minici, R., Ammendola, M., Manti, F., Siciliano, M. A., Minici, M., Komaei, I., Currò, G., & Laganà, D. (2021). Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8–9. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2021.634087

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.